4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE, MN
Receives Positive Listing Determination from Nasdaq
Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Receives FDA Approval to Advance Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data
Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
News, Material Contracts
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Extinguishes Over $32 Million in Debt, Strengthening Balance Sheet
Q2
Q1
FY 2024
Q3
FY 2023
Q3 amended
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence